Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MGMT | P16455 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002256 | 1.00 | LGALS8 (0.42) | LGALS8CA1CA2CA9PDCD1 | |
| SCHEMBL2003046 | 0.85 | LMNA (0.50) | LGALS8CA1CA2CA9LMNA | |
| SCHEMBL7768969 | 0.84 | LGALS8 (0.51) | LGALS8CA1CA2CA9 | |
| SCHEMBL8537936 | 0.79 | LGALS8 (0.61) | LGALS8CA1CA2CA9 | |
| SCHEMBL9238485 | 0.79 | LGALS8 (0.61) | LGALS8CA1CA2CA9 | |
| SCHEMBL8537938 | 0.79 | LGALS8 (0.61) | LGALS8CA1CA2CA9 | |
| SCHEMBL8822976 | 0.79 | LGALS8 (0.46) | LGALS8CA1CA2CA9 | |
| SCHEMBL11070746 | 0.79 | LGALS8 (0.46) | LGALS8CA1CA2CA9 | |
| SCHEMBL11302596 | 0.79 | LGALS8 (0.46) | LGALS8CA1CA2CA9 | |
| SCHEMBL20985069 | 0.79 | MAPK1 (0.53) | PDCD1CD274LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960523-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080033155-A1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-7288640-B2 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107600-A1 | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor | DDOST, AGL, GALE | LGALS8 124/4885CA1 2215/4885CA2 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.